NCT00753480View on ClinicalTrials.gov

A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PHASE1SuspendedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2008

Conditions
Fallopian Tube CancerOvarian CancerPeritoneal Cancer
Interventions
DRUG

D4064A

Trial Locations (2)

10065

Investigational Site, New York

37203

Investigational Site, Nashville

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY